"买进口健康品，到底该看什么？""自己用的'惯爱'，以后品质能更靠谱吗？" 近日，惯爱核心团队远赴 美国，实地探访独家代理品牌 COPTIMAL 的 S 级智能工厂，不仅揭秘了 "好产品是怎么造出来的"，更 给中国消费者带来了关于 "品质、效果、安心" 的明确答案 —— 无论是跨境买的 COPTIMAL，还是本 土选的 "惯爱"，未来都能享受到全球顶尖工厂的生产保障。 消费者最关心的 "安全感"：这家工厂用 10 余项认证 +"鹰眼监控" 守护 比如常熬夜、想改善睡眠又想护肤的人，COPTIMAL 红笛鲷时光睡美人饮有实打实的数据：2 周毛孔 能减少 13.1%，4 周胶原蛋白密度提升 23.0%，还拿了 10 个国际奖项、7 项专利。"不是光说好听，有 实验证明能调节睡眠激素、修复肌肤，刚好匹配现在 65% 中国人有睡眠困扰的需求"。 走进 COPTIMAL 美国工厂，最先让消费者放心的，是墙上挂满的 "硬认证"：SQF LEVEL 3 食品安全标 章(全球食品外销的 "最高通行证"，从原料到成品每一步都要达标)、美国 NSF GMP、英国 BRC…… 足 足 10 多项国际认证，甚至还有少见的 "能源管理 ...

Core Insights - Yunnan Baiyao reported a stable performance in 2024 with total revenue of 40.033 billion yuan, a year-on-year increase of 2.36%, and a net profit of 4.749 billion yuan, up 16.02% [1] - The health product segment showed a significant slowdown in growth at 1.6%, contrasting with the pharmaceutical segment's growth of 11.8% [1] Pharmaceutical Segment - The pharmaceutical segment achieved a revenue of 6.924 billion yuan, growing by 11.8%, with key products like aerosol sales exceeding 2.1 billion yuan, a growth of over 26% [2] - Traditional Chinese medicine products such as Pudilan and Xuesaitong capsules also performed well, each surpassing 100 million yuan in sales [2] - Despite strong performance in traditional pharmaceuticals, the company's innovation in drug development is lagging, with no detailed progress reported on new drug initiatives [2] Health Product Segment - The health product segment generated revenue of 6.526 billion yuan, with a modest growth of 1.6% and a profit of 2.191 billion yuan, up 8.36% [3] - Yunnan Baiyao toothpaste maintains the largest market share in China, while Yangyuanqing personal care products saw a revenue increase of 30.3% [3] - The competitive landscape in health products is intensifying, particularly in oral care and hair loss prevention, necessitating innovation and market expansion to maintain market share [3][4] Chinese Medicine Resource Segment - The Chinese medicine resource segment reported external revenue of 1.751 billion yuan, a growth of 3.13%, benefiting from supply chain synergies [5] - The company implemented a "big procurement" integrated management platform, reducing procurement costs by 31 million yuan [5] - Despite these efficiencies, the company needs to enhance its digital transformation efforts, as specific outcomes from the "Smart Cloud Medicine" platform were not disclosed [5] Overall Assessment - Yunnan Baiyao's 2024 performance is stable, but challenges exist in the health product segment's growth, insufficient innovation in pharmaceuticals, and the need for improved digital transformation [5]